Skip to content
Screener

Arvinas ARVN Operating Cash Flow

Operating Cash Flow at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$96.57M-52.9%
LON
LeonaBio, Inc.LONA
-$20.9M-42.5%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$54.07M+9.7%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
-$44.11M-27.1%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
-$15.07M+16.6%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$41.89M+38.4%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$572.13M+18.3%
Enterprise value$493.43M+30.3%
P/S6.4×+5.1×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: Arvinas’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 5:18 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033669
(dollars in millions)For the Three Months Ended March 31, 2026For the Three Months Ended March 31, 2025
Accounts payable and accrued liabilities(6.8)(0.8)
Operating lease liability(0.4)(0.5)
Deferred revenue(15.6)(188.9)
Net cash used in operating activities(69.2)(88.9)
Cash flows from investing activities:
Purchases of marketable securities(178.9)(119.6)
Maturities of marketable securities165.0189.5
Sales of marketable securities28.9

Item 1. Financial Statements (Unaudited)

FAQ

What is Arvinas's operating cash flow?
Arvinas (ARVN) reported operating cash flow of -$69.2M in Q1 2026.
How has Arvinas's operating cash flow changed year-over-year?
Arvinas's operating cash flow increased by 22.2% year-over-year, from -$88.9M to -$69.2M.
What is the long-term trend for Arvinas's operating cash flow?
Over 3 years (2021 to 2025), Arvinas's operating cash flow has grown at a -22.8% compound annual growth rate (CAGR), from $595.1M to -$273.8M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about Arvinas's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude